Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al

Slides:

Advertisements

Similar presentations

Volume 46, Issue 6, Pages (December 2004)

Advertisements

Volume 59, Issue 2, Pages (February 2011)

Volume 65, Issue 6, Pages (June 2014)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 65, Issue 2, Pages (February 2014)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks Marcus G.

Volume 69, Issue 4, Pages (April 2016)

Volume 57, Issue 3, Pages e22-e23 (March 2010)

Volume 60, Issue 1, Pages (July 2011)

Volume 66, Issue 3, Pages (September 2014)

Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine Carolyn D. Hurst, Fiona M. Platt, Margaret.

Volume 69, Issue 4, Pages (April 2016)

Volume 65, Issue 6, Pages (June 2014)

Volume 71, Issue 2, Pages (February 2017)

Epigenetics in Prostate Cancer: Biologic and Clinical Relevance

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 5, Pages (November 2007)

Re: Marcus G. Cumberbatch, Matteo Rota, James W. F

Volume 72, Issue 4, Pages (October 2017)

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Volume 65, Issue 2, Pages (February 2014)

Cholinergic Innervation and Muscarinic Receptors in the Human Prostate

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 2, Issue 2, Pages (February 2014)

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 63, Issue 6, Pages (June 2013)

Volume 66, Issue 4, Pages (October 2014)

Prostate Cancer Detection: A View of the Future

On Molecular Classification of Bladder Cancer: Out of One, Many

Volume 50, Issue 4, Pages (October 2006)

Volume 63, Issue 5, Pages (May 2013)

On the Origin of Syn- and Metachronous Urothelial Carcinomas

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Shaheen Alanee, Kasmintan Schrader, Kenneth Offit European Urology

Volume 57, Issue 4, Pages e41-e42 (April 2010)

Inflammation and Chronic Prostatic Diseases: Evidence for a Link?

Prostate Cancer Epidemic in Sight?

Volume 59, Issue 3, Pages e7-e8 (March 2011)

Volume 70, Issue 1, Pages e27-e28 (July 2016)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Mark A. Rubin, Gabriele Girelli, Francesca Demichelis European Urology

Volume 56, Issue 1, Pages (July 2009)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 67, Issue 1, Pages 7-10 (January 2015)

The Lethal Clone in Prostate Cancer: Redefining the Index

Volume 68, Issue 6, Pages e134-e135 (December 2015)

Volume 73, Issue 1, Pages 4-8 (January 2018)

Volume 70, Issue 3, Pages e72-e74 (September 2016)

Volume 65, Issue 2, Pages (February 2014)

The Economic Costs of Overactive Bladder in Germany

TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential Liang Cheng, Rodolfo Montironi,

Volume 50, Issue 5, Pages (November 2006)

Re: Christine McKillop

Volume 53, Issue 6, Pages (June 2008)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Testicular Cancer Variations in Time and Space in Europe

Jacques Irani European Urology Supplements

Volume 53, Issue 1, Pages (January 2008)

Volume 54, Issue 4, Pages (October 2008)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Economic Burden of Bladder Cancer Across the European Union

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Volume 53, Issue 2, Pages (February 2008)

Volume 54, Issue 1, Pages (July 2008)

Presentation transcript:

Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al. Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome. Eur Urol 2014;65:360–6 Jayant K. Rane, Matthew S. Simms, Norman J. Maitland European Urology Volume 65, Issue 6, Pages e85-e86 (June 2014) DOI: 10.1016/j.eururo.2014.02.030 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Telomerase reverse transcriptase (TERT) expression changes during prostate epithelial pathophysiology. (a) Quantitative reverse transcription polymerase chain reaction analysis of human TERT expression in prostate epithelial subpopulations enriched from normal prostate (n=3), prostate epithelium (n=5), and prostate cancer cell lines; (b) schematic representation showing telomerase dynamics in normal prostate and proposed changes during carcinogenesis. Data are plotted as mean plus or minus standard deviation. Significance is calculated by the student two-tailed t test (** p<0.01; *** p<0.001). BPH=benign prostatic hyperplasia; CB=committed basal cells; CRPC=castration-resistant prostate cancer; hTERT=human telomerase reverse transcriptase; LC=luminal cells; mRNA=messenger RNA; ND=not detectable; PCa=treatment-naive prostate cancer (Gl 7); PIN=prostatic intraepithelial neoplasia; SC=stemlike cells; TA=transit-amplifying cells. European Urology 2014 65, e85-e86DOI: (10.1016/j.eururo.2014.02.030) Copyright © 2014 European Association of Urology Terms and Conditions